BioSpace News Archive

Actinium Pharmaceuticals, Inc. today highlighted its activity at the upcoming Transplantation & Cellular Therapy (TCT) Tandem Meetings of ASTCT and CIBMTR, the combined annual meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) being held April 23 – 26, 2022 virtually and in Salt Lake City, Utah.

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 first quarter financial results before the opening of the market on April 26, 2022.

Aruvant Sciences, a private company focused on developing gene therapies for rare diseases, announced that the company will participate in multiple conferences this Spring.

Cyclacel Pharmaceuticals, Inc. announced dosing of the first patient in the Company’s streamlined, multi-cohort Phase 1/2 study of oral CYC140 in patients with advanced solid tumors and lymphomas.

Therapeutic Solutions International announced today data demonstrating its JadiCell™ adult stem cell product induces multiplication of specific lung cells which are believed to give rise to new lung tissue which compensate for damaged cells.

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), announced today that CoSara Diagnostics Pvt Ltd (“CoSara,” or the “JV”), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization (“CDSCO”) in India to manufacture and sell its SARAQ™ Hepatitis C (“HCV”) Viral Load Kit as an in vitro diagnostic (“IVD”).

Ambu continues to advance the market for single-use endoscopy by addressing Fibreoptic Endoscopic Evaluation of Swallowing.

Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device company offering patented, best-in-class, single use smart safety syringe products, today announced the closing of its initial public offering of 3,750,000 units at a public offering price of $4.25 per unit.

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (“Genomma Lab” or “the Company”), today announced that it will report its First Quarter 2022 results on Wednesday, April 27, 2022 after the Mexican Market (BMV) close.

The global companion diagnostics market is expected to reach the value of US$ 9.30 Bn by the end of 2030 and it is estimated to expand at a CAGR of 9% from 2021 to 2030.